Hybrid Polypeptides Merging GLP-1 and Exendin-4 for Metabolic Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for metabolic diseases such as diabetes and obesity lack effective agents that can control plasma glucose levels, insulin levels, and insulin secretion, with existing therapies having limitations in duration of action, efficacy, and side effects.
Innovation Solution
Development of hybrid polypeptides combining bio-active peptide hormone modules from components like GLP-1, exendin-4, amylin, and others, linked to enhance stability, bioavailability, and receptor interaction, to create therapeutic agents for metabolic disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If GLP-1 is used for prolonged therapy of diabetes, then glucose control efficacy is improved, but serum half-life is too short to maintain therapeutic effect
Solution Approach 1:
The patent combines GLP-1 with exendin-4 to create a hybrid polypeptide that merges the insulinotropic effects of GLP-1 with the extended half-life properties of exendin-4, resolving the contradiction between therapeutic efficacy and duration of action
Solution Approach 2:
The invention creates a composite peptide structure by fusing GLP-1 and exendin-4 sequences, resulting in a hybrid molecule that exhibits both the glucose-lowering potency of GLP-1 and the metabolic stability of exendin-4
2Duration of action of stationary object
If hybrid polypeptides are designed to enhance stability and bioavailability, then therapeutic duration is improved, but molecular complexity increases
Solution Approach 1:
The hybrid polypeptide is designed as segmented modules where distinct functional regions of GLP-1 and exendin-4 are preserved and linked by a peptide bond, allowing each segment to contribute its specific properties while maintaining overall stability and extended duration of action
Solution Approach 2:
The invention applies local quality by preserving the insulinotropic-active regions of GLP-1 while incorporating the stable C-terminal amide and disulfide bridge structures of exendin-4, ensuring that each local region contributes its specific functional property to the hybrid molecule
Data Source
AI summary
The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.